Consun Pharmaceutical Group Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:C1P Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
05 Nov 24	Buy€476,115	Lion River I N.V.	Company	491,000	€0.97
17 Sep 24	Buy€63,078	Meng An	Individual	92,000	€0.69
16 Sep 24	Buy€233,347	Meng An	Individual	350,000	€0.67
13 Sep 24	Buy€197,885	Meng An	Individual	295,000	€0.67
12 Sep 24	Buy€563,666	Meng An	Individual	856,000	€0.66
11 Sep 24	Buy€670,615	Meng An	Individual	1,021,000	€0.66
10 Sep 24	Buy€335,674	Meng An	Individual	518,000	€0.65
05 Sep 24	Buy€177,167	Meng An	Individual	290,000	€0.61
04 Sep 24	Buy€537,000	Meng An	Individual	830,000	€0.65
03 Sep 24	Buy€656,269	Meng An	Individual	1,009,000	€0.65
02 Sep 24	Buy€621,099	Meng An	Individual	950,000	€0.65
29 Aug 24	Buy€58,556	Meng An	Individual	90,000	€0.65
28 Aug 24	Buy€219,349	Meng An	Individual	340,000	€0.65
05 Jul 24	Buy€906,911	Meng An	Individual	1,300,000	€0.70
04 Jul 24	Buy€33,935	Meng An	Individual	50,000	€0.68
03 Jul 24	Buy€81,770	Meng An	Individual	123,000	€0.66
06 Jun 24	Sell€993,936	Quan Zhu	Individual	1,287,700	€0.77
06 Jun 24	Buy€607,573	Quan Zhu	Individual	1,287,700	€0.47
21 May 24	Sell€7,288,993	Yubao An	Individual	9,219,000	€0.79

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of C1P?
Owner Type	Number of Shares	Ownership Percentage
VC/PE Firms	42,907,000	5.17%
Institutions	71,214,185	8.58%
General Public	336,845,418	40.6%
Individual Insiders	378,857,354	45.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.7%.

Top Shareholders

Top 25 shareholders own 59.14% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
25%	Yubao An	207,737,455	€197.9m	-4.25%	no data
13.3%	Wai Po Young	110,050,000	€104.8m	0%	no data
5.17%	Lion River I N.V.	42,907,000	€40.9m	0%	47.15%
4.63%	Qian Li	38,424,899	€36.6m	-59.3%	no data
2.73%	Meng An	22,645,000	€21.6m	55.8%	no data
2.17%	The Vanguard Group, Inc.	18,037,474	€17.2m	-0.36%	no data
1.9%	FMR LLC	15,802,829	€15.1m	0.02%	no data
1.35%	Dimensional Fund Advisors LP	11,187,988	€10.7m	-0.04%	no data
0.41%	AllianceBernstein L.P.	3,362,726	€3.2m	-0.34%	no data
0.31%	Norges Bank Investment Management	2,546,132	€2.4m	0%	no data
0.3%	Fullgoal Fund Management Co. Ltd.	2,518,000	€2.4m	0%	0.01%
0.24%	Bank of Singapore Limited, Asset Management Arm	1,989,310	€1.9m	0%	0.15%
0.24%	BlackRock, Inc.	1,986,000	€1.9m	244%	no data
0.21%	Goldman Sachs Asset Management, L.P.	1,772,000	€1.7m	0%	no data
0.2%	First Trust Advisors LP	1,678,756	€1.6m	0%	no data
0.18%	Teachers Insurance and Annuity Association-College Retirement Equities Fund	1,476,000	€1.4m	413%	no data
0.12%	Thrivent Investment Management Inc.	1,007,000	€959.3k	0%	no data
0.12%	China Southern Asset Management Co., Ltd.	1,000,000	€952.6k	0%	no data
0.1%	Artico Partners AG	845,000	€805.0k	0%	0.95%
0.096%	Union Asset Management Holding AG	793,000	€755.4k	0%	no data
0.086%	AXA Investment Managers S.A.	714,000	€680.1k	0%	no data
0.085%	State Street Global Advisors, Inc.	707,400	€673.9k	-1.12%	no data
0.077%	American Century Investment Management Inc	637,012	€606.8k	0%	no data
0.072%	Mackenzie Financial Corporation	599,000	€570.6k	0%	no data
0.045%	Segall Bryant & Hamill, LLC	370,492	€353.0k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/12 07:39
End of Day Share Price	2025/01/10 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Consun Pharmaceutical Group Limited is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Fangqi Dai	China Merchants Securities (HK) Co., Ltd
null null	CMB International Securities Limited
Trina Chen	Credit Suisse